Microbiome Based Diagnostic for Inflammatory Bowel Disease
Biomecite Diagnostics, LLC, VA, United States
Biomecite Diagnostics is commercializing an Inflammatory Bowel Disease (IBD) diagnostic based on a microbiome signature technology developed at the University of Maryland, Baltimore. The technology uses a statistical, computational method to rapidly and comprehensively characterize and compare metagenomic data based on sequence composition.
Primary Application Area: Medical Devices
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
FIGURES OF MERIT
Value Proposition: The diagnostic test for IBS and IBD will provide a non-invasive alternative or supplement to currently used endoscopy-based tests, particular in sensitive pediatric populations. The test will be less expensive and more accurate than existing solutions.
Organization Type: Early-stage Startup (Seed)
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: The team has received MII Phase 2 funding from TEDCO in Maryland
Primary Sources of Funding: Other
Looking for: Both Funding and Development Partners